SE8406416L - PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER - Google Patents

PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER

Info

Publication number
SE8406416L
SE8406416L SE8406416A SE8406416A SE8406416L SE 8406416 L SE8406416 L SE 8406416L SE 8406416 A SE8406416 A SE 8406416A SE 8406416 A SE8406416 A SE 8406416A SE 8406416 L SE8406416 L SE 8406416L
Authority
SE
Sweden
Prior art keywords
level
human cancer
urine
diagnosis
procedure
Prior art date
Application number
SE8406416A
Other languages
Swedish (sv)
Other versions
SE8406416D0 (en
Inventor
B S Vold
Original Assignee
Stanford Res Inst Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/532,998 external-priority patent/US4665018A/en
Application filed by Stanford Res Inst Int filed Critical Stanford Res Inst Int
Publication of SE8406416D0 publication Critical patent/SE8406416D0/en
Publication of SE8406416L publication Critical patent/SE8406416L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human cancer is diagnosed/monitored by measuring the levels of certain modified nucleosides, such as N-[9-( beta -D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine, in the urine of a subject by a quantitative immunoassay that preferably employs a monoclonal anti-modified nucleoside antibody and comparing that level to the level of the modified nucleoside that occurs in the urine of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of the modified nucleoside present in urine specimens taken from the subject at different times.
SE8406416A 1983-09-16 1984-12-17 PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER SE8406416L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/532,998 US4665018A (en) 1983-04-18 1983-09-16 Methods and test kit for diagnosing/monitoring cancer in humans

Publications (2)

Publication Number Publication Date
SE8406416D0 SE8406416D0 (en) 1984-12-17
SE8406416L true SE8406416L (en) 1984-12-17

Family

ID=24124035

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8406416A SE8406416L (en) 1983-09-16 1984-12-17 PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER

Country Status (2)

Country Link
GB (1) GB2150690B (en)
SE (1) SE8406416L (en)

Also Published As

Publication number Publication date
SE8406416D0 (en) 1984-12-17
GB2150690B (en) 1987-07-01
GB8430629D0 (en) 1985-01-09
GB2150690A (en) 1985-07-03

Similar Documents

Publication Publication Date Title
Arbesman et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid
Bloomer et al. α-Fetoprotein in nonneoplastic hepatic disorders
Close et al. Cigarettes, alcohol and marijuana are related to pyospermia in infertile men
Van Lieshout et al. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections
Hjiyiannakis et al. Thyroglobulin antibodies in differentiated thyroid cancer
BIGGAR et al. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984
NO160746C (en) PROCEDURE FOR DETECTING OCCULT BLOOD IN FACES TESTS.
Palmqvist et al. Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study
ATE376187T1 (en) DETECTION OF DISEASES OF THE KIDNEYS AND TREATMENT
Radl Light chain typing of immunoglobulins in small samples of biological material
DK0516746T3 (en) Oral collection for immunoassay
NO163254C (en) TESTING DEVICE FOR OCCULT BLOOD DETECTION.
Paimela et al. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis
DE3780480D1 (en) TEST FOR HUMAN BREAST CANCER.
Mayne et al. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
Farr et al. Assessment of rheumatoid activity based on clinical features and blood and synovial fluid analysis.
Kalwinsky et al. Clinical utility of initial terminal deoxynucleotidyl transferase determinations in childhood acute leukemias
SE8406416D0 (en) PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER
Neel et al. Epstein-Barr virus-related antibody: Changes in titers after therapy for nasopharyngeal carcinoma
NO168311C (en) MONOCLONAL ANTIBODIES FOR HUMAN NON-TASTE LUNGCARCINOMES, CELL LINES PRODUCING THESE AND DIAGNOSTIC KITS
SE8306661D0 (en) PROCEDURE AND TEST RATE FOR DIAGNOSIS OF HUMAN CANCER
Virdee et al. The Association between Blood Test Trends and Undiagnosed Cancer: A Systematic Review and Critical Appraisal
Brown et al. Skin immunopathology in systemic lupus erythematosus
Paranjape et al. Identification of circulating parasite antigen in patients with bancroftian filariasis.
Monroe Vitiligo associated with regional enteritis

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8406416-1

Effective date: 19900126